The FDA approves new leukemia drug; expands use of current drug.
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use*; D002648:Child; D000069439:Dasatinib; D017277:Drug Approval; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D011743:Pyrimidines; D013844:Thiazoles; D011092:Polyethylene Glycols; C042705:pegaspargase; D001215:Asparaginase; D000069439:Dasatinib